COLUMBIA, Md., July 10 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that Mead Johnson(R) Nutritionals has received clearance from the U.S. Food and Drug Administration (FDA) to introduce Enfamil(R) Premature LIPIL(TM), a pre-term version of Enfamil(R) LIPIL(TM). LIPIL(TM) contains a blend of Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA), two nutrients that are the building blocks of a baby's brain and eyes. The levels of DHA and ARA used in LIPIL(TM) are consistent with the levels recommended by the World Health Organization and other international organizations and consistent with the levels used in numerous studies that have demonstrated positive effects on infant development. Mead received FDA clearance and launched Enfamil(R) LIPIL(TM) for term infants in the U.S. in February 2002.
"It's a great day for U.S. preemies," stated Henry Linsert, Jr., Chairman and CEO of Martek. "Studies have shown that when you use the right levels of supplementation, in the right triglyceride or breast milk form, you see the right results."
Two large, recent studies have shown statistically significant improvements in growth and development in premature infants fed Enfamil(R) Premature LIPIL(TM). One of these studies was presented at the May 2002 Pediatric Academic Societies' annual meeting and the other appeared in the May 2002 issue of The Journal of Pediatrics. Although some studies have failed to report similar results, these two recent studies add to the growing body of evidence regarding the importance of including DHA and ARA, at the appropriate levels, in the pre-term infant diet.
Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
This press release contains forward-looking statements regarding the commercialization of Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.